

## COVID-9 VACCINATION SUMMARY TABLE

Pfizer-BioNTech					
Age Group	Dose 1	Dose 2	Dose 3	Dose 4	Bivalent Booster
<b>6 months – 4 years</b>	<b>Primary Series</b>	<b>Primary Series</b> ; given 3-8 weeks after 1 <sup>st</sup> dose	<b>Primary Series</b> ; given at least 8 weeks after 2 <sup>nd</sup> dose  <u>Up to Date</u> = 2 weeks after 3 <sup>rd</sup> dose	Not yet authorized for this age group	Not yet authorized for this age group
<b>5 – 11 years</b>	<b>Primary Series</b>	<b>Primary Series</b> ; given 3-8 weeks after 1 <sup>st</sup> dose	<b>Booster</b> ; at least 5 months after 2 <sup>nd</sup> dose  <u>Up to Date</u> = immediately after 3 <sup>rd</sup> dose	N/A	Not yet authorized for this age group
<b>12 – 17 years</b>	<b>Primary Series</b>	<b>Primary Series</b> ; given 3-8 weeks after 1 <sup>st</sup> dose	N/A	N/A	<b>Updated Booster</b> ; given at least 2 months after 2 <sup>nd</sup> dose/last booster; <i>can <b>only</b> be Pfizer-BioNTech product</i>  <u>Up to Date</u> = immediately after booster
<b>18 years and older</b>	<b>Primary Series</b>	<b>Primary Series</b> ; given 3-8 weeks after 1 <sup>st</sup> dose	N/A	N/A	<b>Updated Booster</b> ; given at least 2 months after 2 <sup>nd</sup> dose/last booster; <i>can be <b>either</b> Pfizer-BioNTech or Moderna</i>  <u>Up to Date</u> = immediately after booster
Moderna					
Age Group	Dose 1	Dose 2	Dose 3	Dose 4	Bivalent Booster
<b>6 months – 11 years</b>	<b>Primary Series</b>	<b>Primary Series</b> ; given 4-8 weeks after 1 <sup>st</sup> dose  <u>Up to Date</u> = 2 weeks after 2 <sup>nd</sup> dose	N/A	N/A	Not yet authorized for this age group
<b>12 – 17 years</b>	<b>Primary Series</b>	<b>Primary Series</b> ; given 4-8 weeks after 1 <sup>st</sup> dose	N/A	N/A	<b>Updated Booster</b> ; given at least 2 months after 2 <sup>nd</sup> dose/last booster; <i>can <b>only</b> be a Pfizer-BioNTech product</i>  <u>Up to Date</u> = immediately after booster
<b>18 years and older</b>	<b>Primary Series</b>	<b>Primary Series</b> ; given 4-8 weeks after 1 <sup>st</sup> dose	N/A	N/A	<b>Updated Booster</b> ; given at least 2 months after 2 <sup>nd</sup> dose/last booster; <i>can be <b>either</b> Pfizer-BioNTech or Moderna</i>  <u>Up to Date</u> = immediately after booster

Johnson & Johnson (Janssen)					
Age Group	Dose 1	Dose 2	Dose 3	Dose 4	Bivalent Booster
<b>18 – 49 years</b>	<b>Primary Series</b>	N/A	N/A	N/A	<b>Updated Booster</b> ; given at least 2 months after 1 <sup>st</sup> dose/last booster; <i>can be <b>either</b> Pfizer-BioNTech or Moderna</i>  <u>Up to Date</u> = immediately after booster
<b>50 years and older</b>	<b>Primary Series</b>	<b>Booster</b> ; given at least 2 months after 1 <sup>st</sup> dose; <i>can be <b>either</b> Pfizer-BioNTech or Moderna</i>	N/A	N/A	<b>Updated Booster</b> ; given at least 2 months after 2 <sup>nd</sup> dose/last booster; <i>should be <b>either</b> Pfizer-BioNTech or Moderna</i>  <u>Up to Date</u> = immediately after booster
Novavax					
Age Group	Dose 1	Dose 2	Dose 3	Dose 4	Bivalent Booster
<b>12 – 17 years</b>	<b>Primary Series</b>	<b>Primary Series</b> ; given 3-8 weeks after 1 <sup>st</sup> dose	N/A	N/A	<b>Updated Booster</b> ; given at least 2 months after 2 <sup>nd</sup> dose; <i>can <b>only</b> be Pfizer-BioNTech</i>  <u>Up to Date</u> = immediately after booster
<b>18 years and older</b>	<b>Primary Series</b>	<b>Primary Series</b> ; given 3-8 weeks after 1 <sup>st</sup> dose	N/A	N/A	<b>Updated Booster</b> ; given at least 2 months after 2 <sup>nd</sup> dose; <i>can be <b>either</b> Pfizer-BioNTech or Moderna</i>  <u>Up to Date</u> = immediately after booster

\*If you have completed your primary series, but are not yet eligible for a booster, you are considered Up to Date.

Considerations:

People ages 6 months – 64 years, and especially males ages 12 through 39 years may consider getting the 2<sup>nd</sup> primary series dose of an mRNA COVID-19 vaccine (Pfizer-BioNTech or Moderna) 8 weeks after the 1<sup>st</sup> dose. A longer time between the 1<sup>st</sup> and 2<sup>nd</sup> primary series doses may increase how much protection the vaccines offer and further minimize the rare risk of myocarditis and pericarditis.

Anyone wanting protection due to high levels of community transmission, people ages 95 years and older, or people who are more likely to get very sick from COVID-19 should get the second dose of Pfizer-BioNTech COVID-19 vaccine 3 weeks (21 days) after the first dose, Moderna COVID-19 vaccine 4 weeks (28 days) after the first dose, or Novavax COVID-19 vaccine 3 weeks (21 days) after the first dose.

CDC does not recommend mixing products for your primary series doses. Children ages 5 through 11 years who received a Pfizer-BioNTech primary series must also get a Pfizer-BioNTech booster. Teens ages 12-17 years may receive a Pfizer-BioNTech booster regardless of the product used for their primary series. People ages 18 years and older may receive either a Pfizer-BioNTech or Moderna booster regardless of the product used for their primary series. For those 12 years and older, only the updated (bivalent) mRNA booster is authorized; they can no longer receive the original (monovalent) mRNA booster.

Novavax is not authorized for use as a booster at this time.